Sanofi is one of the leading companies in the diabetes field, but its flagship insulin product Lantus is now facing growing competition. The firm is looking at new ways of standing out by ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Sanofi SNY reported third-quarter 2024 adjusted ... driven mainly by higher sales in United States and China. Lantus sales rose 33.8% to €431.0 million. Plavix sales increased 8.3% to €230 ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Our insulin franchise, more specifically Lantus is very resilient and sales ... This transaction marks an important strategic step for Sanofi to become a pure-play and science-focused biopharma ...

Sanofi's wide lineup of branded drugs and vaccines ... launches offsetting patent losses and deteriorating pricing for Lantus. Following a sharp patent cliff in 2013, Sanofi faces relatively ...

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba ...

It has its own manufacturing facility at Goa. It sells products through independent distributors primarily in India.Sanofi India's products viz. Lantus Combiflam Amaryl and Allegra feature in the top ...

A drug pricing expert reveals the shocking cost disparity of a life-saving spinal muscular atrophy drug in India, priced at ...